TechMARK movers: Share buying in Antisoma
LONDON (SHARECAST) - Shares in cancer drug developer Antisoma have had little to cheer about in recent weeks. They plunged at the end of March following news that Novartis had halted a Phase III trial for lung cancer treatment ASA404.
APG Algemene Pensioen Groep NV appears to believe that this is a buying opportunity and it has taken its stake to 3.17% of Antisoma.
The Vectura share price continues to decline. It is more than 5% lower on the week and down by more than one-quarter over the past month. In March, the pharma company agreed to take full control of the US development of asthma treatment VR315 back from Sandoz.
Many investors saw this as a negative and argued that taking on the development increased the risk for Vectura. There were positive reactions and broker FinnCap set a price target of 120p a share at the end of March. However, the negative view appears to be winning out.
www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=3385608
LONDON (SHARECAST) - Shares in cancer drug developer Antisoma have had little to cheer about in recent weeks. They plunged at the end of March following news that Novartis had halted a Phase III trial for lung cancer treatment ASA404.
APG Algemene Pensioen Groep NV appears to believe that this is a buying opportunity and it has taken its stake to 3.17% of Antisoma.
The Vectura share price continues to decline. It is more than 5% lower on the week and down by more than one-quarter over the past month. In March, the pharma company agreed to take full control of the US development of asthma treatment VR315 back from Sandoz.
Many investors saw this as a negative and argued that taking on the development increased the risk for Vectura. There were positive reactions and broker FinnCap set a price target of 120p a share at the end of March. However, the negative view appears to be winning out.
www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=3385608
Keine Kauf Empfehlung!!
Wen nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Wen nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
